

INDEX

Note: Page numbers in *italics* indicate figures;
page numbers followed by t refer to tables.

- Abdominal muscle weakness, 208
Abetalipoproteinemia, 122t
ABLEDATA, 259
Acetazolamide, 204
Acidemias, organic, 116t
Activities of daily living, in severity classification, 184t
Acute attack
 definition of, 185
 optic neuritis in, 186
 relapse after
 criteria for, 185
 severity and responsiveness to treatment of, 185-186
 treatment of
 corticosteroids in, 186-187, 188t
 cytotoxic therapy in, 188t, 189
 intravenous immunoglobulin in, 187, 188t, 189
 methylprednisolone in, 186, 188t
 ONSG trial of, 186-187
 plasma exchange in, 187, 188t, 189
 symptom severity and, 186
Acute disseminated encephalomyelitis, 98t
 differential diagnosis of, in children, 238-239
Adolescence, geographic location in, MS susceptibility and, 27
Adrenoleukodystrophy, 115t
Adult onset autosomal dominant leukodystrophy, 116t
Adult polyglusan body disease, 121t
Affective release, 220
African black population, MS risk in, 31
Aging
 normal, 91
 prognosis and, 228
Alanine transaminase
 in antifatigue drug monitoring, 194t-195t
 in antispasticity drug monitoring, 190t-191t
Alcoholism, 128t
Alfalfa, 245t
Altered ligand treatment, 181
Alternative medicine, 244, 245t
Amantadine (Symmetrel), 194t
Ambulation/movement disorders
 drugs for, 204-205
 frequency of, 203
 mechanical aids for, 203
 prognosis and, 229
 treatment of
 electrical stimulation, surgical ablation, or radiosurgery to brain in, 205
 occupational therapy in, 204
 physical therapy in, 203
 tremor in, 204
American Indians, MS risk in, 31
Amitriptyline, 201t
Amphotericin B, toxic leukoencephalopathy from, 128t
Ampicillin, in pregnancy, 198
Amyloid protein, accumulation during demyelination, 19, 22t
Amyotrophic lateral sclerosis, suicide risk in, 246
Anesthesia
 during childbirth, 235
 controversies in, 232-233
Angioendotheliomatosis, malignant, 124t
Animal models
 of autoimmune disease, 40
 of MS, 35, 41-43, 42, 48
 murine JHM coronavirus, 48
Ankylosing spondylitis, suicide risk in, 246
Anticardiolipid antibodies, 78t
Antidepressants
 herbs interacting with, 245t
 for respiratory symptoms, 214
 tricyclic
 for emotional disorders, 219
 for pain, 199, 201t, 202
Antiemetic, 176
Antigen-presenting cells, T cell interaction with, 44
Anti-inflammatory treatment, pathological MS subtype and, 25
Antimyelin response, 47-48
Antineutrophil cytoplasmic antibodies, 78t
Antinuclear antibodies, 75, 78t
Antiphospholipid antibody syndrome, 106t
Antisocial behavior, 219
Antispasticity drugs, symptom severity classification and, 184t
ARC (formerly Association for Retarded Persons), 258
Arsenic exposure, 128t
Arteriopathy, cerebral autosomal, in CADASIL, 120t
Aspartate aminotransferase
 in antifatigue drug monitoring, 194t-195t
 in antispasticity drug monitoring, 190t-191t
Astrocytes
 reactive proliferation of, 14, 17

residual scattered, 14

Ataxia

- Friedreich, 117t
- in NARP, 118t
- progressive, 94
- spinocerebellar, 117t

Autoimmunity/autoimmune diseases

- common features of, 39-40
- MS link to, 30, 35, 40-41
- in pathological MS subtypes, 22t
- treatment of, 25

Automated imaging, 69

Autonomic disturbances

- in MS, 210
- in paroxysmal attacks, 206

Autopsy, MS findings in, 13

Autoreactive T cells, in MS, 43, 44

Autosomal dominant arteriopathy, cerebral, in CADASIL, 120t

Autosomal dominant leukodystrophy, adult onset, 116t

Avonex (interferon b1a)

- advantages and disadvantages of, 140t
- adverse effects of, 139
- dosage of, 135, 136t, 139, 158
- effectiveness of, 136t, 156, 157
- failure of, 177-178
- laboratory monitoring of, 140t
- for monosymptomatic demyelination, 147, 150
- MRI after, 135, 137t
- patient education about, 173, 175t
- patient monitoring in, 140t
- patient selection for, 141t
- in pregnancy, 154, 236
- for RRMS, 135, 136t, 156-157, 157, 170t, 172
- for SPMS, 139, 159, 160, 170t
- structure of, 135
- studies of, 137t, 139, 142
 - CHAMPS, 94, 142, 146-149, 152
- Web site for, 175t

Axonal damage

- imaging of, 69
- in pathological MS subtypes, 19, 22t-23t

Axonal transection, 19

Azathioprine, 178

B7-costimulatory pathway, 44

Baclofen (Lioresal)

- for nystagmus, 212
- for pain, 189, 190t, 201t, 202
- for paroxysmal attacks, 207

Bactrim (trimethoprim-sulfamethoxazole), 198

Balo concentric sclerosis, 96t

BCG vaccine, 239

Bechet disease, 101t

Belladonna, 245t

Benzene, occupational exposure to, 129t

Benzodiazepines, for respiratory symptoms, 214

Betaseron (interferon b1b)

- advantages and disadvantages of, 140t
- adverse effects of, 139, 142
- clinical trials of, 137t, 139
- dosage of, 136t, 139
- effectiveness of, 136t, 156, 157, 165
- failure of, 177-178
- laboratory monitoring of, 140t
- MRI after, 139t, 165
- patient education about, 139, 175t
- patient monitoring in, 140t
- patient selection for, 141t
- in pregnancy, 154, 236
- for RRMS, 136t, 139, 156, 157, 158, 170t, 172
- for SPMS, 159, 160
- structure of, 139
- Web site for, 175t

Bickerstaff brain stem encephalitis, 98t

Binswanger disease, 107t

Black holes, 52-53

Bladder dysfunction

- drugs for, 196t-197t
- neurogenic, 193
- progression of, 193, 198
- urinary tract infections and, 193, 198-199
- urologist referral for, 198

Blood-brain barrier, 44

Bone marrow transplantation, 181

Botulinum toxin injection, for spasticity, 189

Brain stem dysfunction, 13, 54

- paroxysmal attacks of, 205-207

Brain stem encephalitis, Bickerstaff, 98t

Brain stem lesion, MRI of, 57

Breastfeeding

- cytotoxic drug avoidance during, 237
- disease-modifying treatments during, 236
- postpartum relapse rate and, 237

Bromocriptine, 207

Brucellosis, 110t
 Bupropion (Wellbutrin), 219
 Buspirone, 204
 for respiratory symptoms, 214

 CADASIL (cerebral autosomal dominant arteriopathy, with subcortical infarcts and leukoencephalopathy), 120t
 Cancer, suicide risk in, 246
 Capsaicin, 201t
 Carbamazepine (Tegretol)
 for pain, 199, 200t-201t, 202
 for paroxysmal attacks, 206
 for seizures, 207
 Carbatrol, 201t
 Carbon monoxide poisoning, 128t
 Carbon tetrachloride exposure, 128t
 Cardioembolic disease, 106t
 Caretakers, in promoting hope and optimism, 249-250, 251t
 Casanthranol-docusate (Peri-colase), 210
 Catheter angiography, for vascular conditions, 68
 Caucasian population, MS risk in, 30-31
 CD45, MS link to, 34
 Celiac disease, 113t
 Celiac sprue, 208
 Cellular immunity, 45
 Central nervous system, in MS pathogenesis, 43, 44, 45-47
 Central nervous system lesions, antimyelin response to, 47
 Central nervous system lymphoma, 124t
 Central pontine myelinolysis, 112t
 Central serous chorioretinopathy, 106t
 Cerebellum
 lesion in, MRI of, 57
 pathology of, 13, 14
 Cerebral atrophy, MRI of, 71
 Cerebral autosomal dominant arteriopathy, with subcortical infarcts and leukoencephalopathy (CADASIL), 120t
 Cerebroretinal vasculopathy, 120t
 Cerebrospinal fluid
 antibody pattern in, 45
 characteristic pattern in, 76-77, 79
 in McDonald criteria, 87t
 MRI of, 52-53
 tests on, 78t
 Cerebrovascular conditions, differential diagnosis of, 61, 69, 78t
 Cervical spondylosis, 92
 CHAMPS (Controlled High-risk Subjects Avonex MS Prevention) trial, 94, 142, 146-149, 152

Chemokines, 43, 44
 Chemotherapy
 as disease-modifying treatment, 134, 136t-138t, 140t-141t, 143-145
 leukoencephalopathy after, 125t, 128t
 Chiari malformation, 126t
 Child rearing, by MS patient, 235
 Childhood, MS in
 diagnosis/differential diagnosis of, 238-239
 frequency of, 237
 geographic location and, 27
 Children of MS patients, MS risk in, 31, 32t, 237
 Chronic fatigue syndrome, 72, 89-90, 224. See also *Fatigue in MS*.
 Chronic inflammatory demyelinating polyneuropathy, 98t
 Chronic painter's syndrome, 129t
 Chronic progressive MS, 15
 Ciprofloxacin (Cipro), 198
 Classification of symptom severity, 184t
 Clinical MS presentation. See also *Disease-modifying treatments; Prognosis of MS*.
 acute attack in, 185-187, 188t, 189
 ambulatory/movement disorders in, 203-205
 atypical
 with major neurological findings, 94, 130-132
 with minor but definite neurological findings, 91-94, 131
 with normal or equivocal neurological findings, 89-91, 131
 autonomic disturbances in, 210
 benign paresthesias in, 224
 bladder dysfunction in, 193, 196t-197t, 198-199
 cognitive disorders in, 215-217, 218t
 complicated or intractable, management of, 220-221
 constipation in, 208, 209, 210
 dysphagia in, 210-211
 emotional disorders in, 217, 219-220
 fatigue in, 192-193, 194t-195t, 224
 heterogeneity of, 228
 individual variability in, 228-229
 initial, 77t
 modification of, 228
 neuro-ophthalmological, 211-212
 pain and sensory disturbance in, 199, 200t-201t, 202
 paroxysmal attacks in, 205-207
 in relapse, 185-186
 respiratory difficulty in, 212, 213t, 214
 sexual disturbance in, 207-208
 somatization disorder in, 224

spasticity in, 189
 drugs for, 189, 190t-191t, 192
 invasive treatment of, 189, 192
 progression of, 189
 symptom severity classification in, 184t
 time to worsening in, 231t
 typical, 13, 73, 75-76, 131
 Clinical MS subtypes, 15, 16, 17
 Clinically isolated syndromes (CSI)
 cardinal features of, 96t
 clinical trials of, 147-149
 conversion to MS
 Kaplan-Meier estimates of, 147, 148
 likelihood based on neurological symptoms, 226
 MRI prediction of, 54-55, 56t, 57, 60t
 time interval in, 58
 disease-modifying treatment of, 146-150, 150
 in McDonald Committee criteria, 80t-81t, 83t
 MRI of, 96t
 Clonazepam, 204, 206
 for nystagmus, 212
 for paroxysmal attacks, 206
 for tremor, 204
 Cobalamin deficiency or dysmetabolism, 112t
 Cocaine, toxic effects of, 128t
 Cogan syndrome, 104t
 Cognitive disorders
 frequency of, 215
 patient perception of, 216
 screening for, 215-216
 treatment of, 216-217, 218t
 Colase (docusate), 210
 Complementary medicine, 244, 245t
 Computerized tomography (CT)
 limitations of, 68
 myelography with, 68
 Conjugal MS, 31
 Consortium of Multiple Sclerosis Centers, 259
 Constipation
 causes of, 208
 management of, 208, 209, 210
 Contraception in MS, 233-235
 Controlled High-risk Subjects Avonex MS Prevention (CHAMPS)
 trial, 94, 142, 146-149, 152
 Controversial issues in MS
 anesthesia as, 232-233

 in disease-modifying treatments, 180-181
 therapeutic timing as, xi
 Conversion to MS, of isolated symptoms, MRI prediction of, 54-55, 56t, 57, 60t
 Copaxone (glatiramer)
 advantages and disadvantages of, 140t
 adverse effects of, 156-157, 172
 in children, 239
 dosage of, 136t, 143
 effectiveness of, 136t, 143, 156, 157, 166
 failure of, 177-178
 laboratory monitoring of, 140t
 MRI after, 137t
 patient education about, 173, 175t
 patient monitoring in, 140t
 patient selection for, 141t
 for PPMS, 143
 in pregnancy, 154, 236
 for RRMS, 136t, 143, 156-157, 157, 170t-171t, 172
 for SPMS, 159, 160
 structure of, 142
 studies of, 137t
 Web site for, 175t
 Copolymers, as disease-modifying treatment, 134, 136t-138t, 140t-141t, 142-143, 169
 Coronary artery disease, 240
 sildenafil contraindication with, 208
 Corpus callosum, MRI lesions in, 52-53
 Corticosteroids, 161, 171t
 for acute attacks, 186-187, 188t
 dependence on, 187
 herbs interacting with, 245t
 oral vs intravenous, 186
 during pregnancy, 236
 Cousins, MS risk in, 32t
 Cranial nerve functions, lower, in dysphagia, 211
 Creutzfeldt-Jakob disease, new variant, 109t
 CSI. See *Clinically isolated syndromes*.
 Cyclophosphamide, 178, 188t
 Cyclosporine, toxic leukoencephalopathy from, 128t
 Cylert (pemoline), 194t
 Cytokines, proinflammatory, 45
 Cytotoxic therapy
 for acute attack, 188t, 189
 teratogenicity of, 237

 Dalmane (flurazepam), 188t

Dantrolene (Dantrium), 189, 190t
 DDAVP (desmopressin acetate), 197t
 Decompression, neurovascular, 202
 Deconditioning, sildenafil contraindication with, 208
 Definite MS on clinical grounds, in McDonald Committee criteria, 80t-82t
 Definition of MS, 13
 Degenerative disorders, differential diagnosis of, 95, 108t-114t
 Degos disease, 105t
 Dehydration, 208, 240
 Dementia, 94
 Demos Medical Publishing, 255-257
 Demyelinating polyneuropathy, chronic inflammatory, 98t
 Demyelination
 differential diagnosis of, 69, 70
 by macrophages, 18
 monosymptomatic, xi, 96t
 Avonex for, 147
 clinical trials of, 147-149
 disease-modifying treatment of, 146-150, 150
 in McDonald Committee criteria, 80t-81t, 83t. See also *Clinically isolated syndromes*.
 MRS of, 70
 in pathological MS subtypes, 22t
 patterns of, 24t
 plaques in, 13, 14, 17, 19
 signs and symptoms of, 75
 T2-weighted MRI in, 75
 treatment of, timing of, 1
 veterinary, 43
 Desipramine, 201t
 Desmopressin acetate (DDAVP), 197t
 Desyrel (trazodone), 219
 Detrol (tolterodine), 196t-197t
 Detrusor hypoactivity, 198
 Devic disease, 97t
 Diabetes, juvenile, 41
 Diagnosis/differential diagnosis of MS
 algorithm for, 74
 in atypical MS presentation
 with major neurological findings, 94, 130-132
 with minor but definite neurological findings, 91-94, 131
 with normal or equivocal neurological findings, 89-91, 131
 in children, 238-239
 dissemination in space in, 79, 80t-81t, 87t
 dissemination in time in, 79, 80t, 88t
 evoked potentials in, 76

 follow-up visits in, 93
 formula for, 79
 genetic, 85t
 genetic degenerative, 115t-123t
 immunological, 95, 96t-100t
 infectious, 95, 108t-111t
 inflammatory/rheumatological, 95, 101t-103t
 localized disease in, 80t-82t
 lumbar puncture in, 76
 McDonald Committee criteria for. See *McDonald Committee criteria for MS*.
 metabolic, 112t-114t
 monosymptomatic attack in, 80t-81t, 83t, 96t
 MRI in, 71-72. See also *Magnetic resonance imaging*.
 multifocal attack in, 80t-82t
 neurological, 84t, 88
 no better explanation in, 79, 83-84
 oncological, 95, 124t-125t
 plaques in, 13, 14
 primary-progressive disease in, 80t-81t, 83t
 psychiatric, 86t
 revealing to patient, 224-226, 225t
 spinal cord diseases in, 95, 126t-127t
 strict clinical and MRI criteria for, 75
 suggested workup for, 78t
 toxic and miscellaneous, 95, 128t-129t
 in typical MS presentation, 73, 75-76, 131
 uncertainty of, patient coping with, 224
 vascular, 104t-107t
 visual evoked responses in, 76, 78t, 83t, 85
 Diazepam (Valium), 189, 190t
 Diet in MS, 240-241
 Diffusion tensor imaging (DTI), 69
 Diffusion-weighted MRI, 52-53, 69
 Dilantin (phenytoin)
 for pain, 201t, 202
 for seizures, 207
 Diphtheria immunization, 242t-243t
 Diplopia, 205, 212
 cause of, 13
 Disability benefits, 247-248
 Disease associations, MS risk and, 30
 Disease-modifying treatments, 255. See also specific drugs.
 administration of, practical aspects of, 173-174, 175t-177, 177-178
 allergy to, 154
 during breastfeeding, 236

chemotherapy in, 134, 136t-138t, 140t-141t, 143-145
 controversies in, 180-181
 copolymers in, 134, 136t-138t, 140t-141t, 142-143
 FDA-approved, 133-146
 future developments in, 178-182
 immunosuppression in, 146
 individual variations in. See also specific drugs.
 caused by therapy, 164-166, 167
 caused by untreated natural disease variations, 164-165
 interferons in, 134-135, 136t-138t, 139, 140t-141t, 142
 intravenous immunoglobulin in, 145
 intravenous methylprednisolone in, 146
 for monosymptomatic demyelination, 146-150, 150, 168-169
 patient counseling in, 166-168
 patient education/compliance in, 155
 plasma exchange in, 145
 for PPMS, 161, 162
 in pregnancy, 154, 236
 for PRMS, 161, 163, 163
 for RRMS, 150-159, 151, 153, 157, 169, 170t-171t, 172
 for SPMS, 159, 160, 161
 teratogenicity of, 236
 timing of
 MRI sensitivity/specificity and, 58
 for RRMS, 152-154
 Dissemination of lesions, in space and time, 79, 80t-81t, 87t
 Ditropan (oxybutynin), 196t
 Diverticulosis, 208
 DNA, plaque antibody directed against, 46
 Docusate (Colase), 210
 DRB1*1501 gene, MS link to, 34
 Driving a vehicle, 204
 DR2 haplotype, MS link to, 34
 Dysesthetic extremity pain, 199, 202
 Dysphagia, 210-211
 Dystonic symptoms, of paroxysmal attacks, 206

 EAE. See *Experimental allergic/autoimmune encephalitis*.
 Eale disease, 95, 101t
 Early Treatment of Multiple Sclerosis Study (ETOMS), 94, 142, 147-149, 152
 Eastern Paralyzed Veterans Association, 259
 Echinacea, 245t
 Ecstasy (MDMA), toxic effects of, 128t
 EDSS. See *Expanded Disability Status Scores*.
 Electrical stimulation of brain
 for ambulation/movement disorders, 205

 for emotional disorders, 219
 Emotional disorders
 drugs for, 219
 electroshock therapy for, 219
 patient perception of, 217, 219
 psychiatric referral for, 219-220
 range of, 217, 219-220
 Employment, 247-248
 Encephalitis
 Bickerstaff brain stem, 98t
 chronic, in Eale disease, 101t
 Encephalomyelitis, acute disseminated, 98t
 in children, 238-239
 differential diagnosis of, 238-239
 Encephalomyelopathy, subacute necrotizing, 119t
 Encephalopathy
 Hashimoto, 95, 112t
 in MNGIE, 118t
 Endothelial adhesion molecules, 43, 44
 Endotheliopathy, in HERNS, 120t
 Environment
 autoimmune disease and, 40
 MS risk and, 30, 36
 toxins in, 128t
 Eosinophilia-myalgia syndrome, 103t
 Ephedra, 245t
 Epidemics, MS risk and, 27, 29
 Epidemiology of MS, 27, 28-29, 29-30
 Epilepsy, myoclonic, in MERRF, 118t
 Epileptic seizures, 207
 Equator, distance from, MS risk and, 27, 28-29, 29
 Erectile dysfunction, 207-208
 Erythrocyte sedimentation rate, 78t
 Etiology of MS, 47-49
 ETOMS (Early Treatment of Multiple Sclerosis Study), 94, 142, 147-149, 152
 Euphoria, 219
 European SP Betaferon trial, 139
 EVIDENCE, 142, 156
 Evoked potential studies, 76, 78t, 93
 Exercise in MS, 240-241
 Exhaustion, 240
 Expanded Disability Status Scores (EDSS)
 clinical correlation with, 64
 disease-modifying drugs and, 136t, 172t
 drug timing and, 180
 explanation of, 60t

MRI prediction of, 59
 prognosis and, 230t-231t
 Experimental allergic/autoimmune encephalitis (EAE)
 as MS model, 41-43
 treatment of, 42
 Extracellular matrix, chemokine degradation of, 43, 44
 Extrapontine myelinolysis, 112t
 Extremities
 dysesthetic pain in, 199, 202
 tremor in, 204

 Fabry disease, 116t
 Familial aggregation of MS, 31, 32t
 Fat intake, 241
 Fatigue in MS, 224. See also *Chronic fatigue syndrome*.
 causes of, 192
 treatment of
 drugs in, 192, 194t-195t
 during pregnancy, 236
 sleep habits in, 193
 Fecal impaction/incontinence, 208
 Fever, 232
 Fibromyalgia, 90
 Five-year rule of Kurtzke, 229
 Flexor spasms, differential diagnosis of, 206
 Fluid attenuated inversion recovery (FLAIR) MRI, 52-53
 Fluoxetine (Prozac)
 for bladder dysfunction, 194t
 for emotional disorders, 219
 Flurazepam (Dalmane), 188t
 Folate deficiency or dysmetabolism, 113t
 Food and Drug Administration (FDA), disease-modifying treat-
 ments approved by, 133-146
 Fresh frozen plasma, 188t
 Friedreich ataxia, 117t
 Functional magnetic resonance imaging (fMRI), 69

 Gabapentin (Neurontin)
 for nystagmus, 212
 for pain, 199, 200t, 202
 for paroxysmal attacks, 207
 Gadolinium infusion studies, 53, 57
 sensitivity and specificity of, 55
 Gag reflex, 211
 Garlic, 245t
 Gastrointestinal encephalopathy, in MNGIE, 118t

Gender
 MS prognosis and, 228
 MS susceptibility and, 27
 Genetic disorders, differential diagnosis of, 115t-123t
 Genetics of MS, 30-31, 32t-33t, 34-35
 in diagnosis, 85t
 environment interaction with, 36-37
 Genome screens, MS linkage in, 34-35
 Geography, MS susceptibility and, 27, 28-29
 Ginseng, 245t
 Glatiramer. See *Copaxone*.
 Glial tumor, 207
 Gliosis, 14
 Globoid cell leukodystrophy, 115t
 Glue sniffing, 128t
 Gluten sensitivity, 113t
 Glutethimide, 204
 Glycoprotein, myelin-associated, 22t-23t
 Gray matter-white matter junction, lesions in, 53, 55, 57

 Hashimoto encephalopathy, 95, 112t
 Head MRI, spinal MRI correlation with, 67
 Heat, avoidance of, 232, 240
 Heisenberg clinical uncertainty principle, 169
 Helper T cells, 45
 Hemiplegia, 94
 Henbane, 245t
 Hepatitis A immunization, 242t-243t
 Hepatitis B immunization, 239, 242t-243t
 Hepatitis B virus, immune response to, 39
 Hepatitis C virus, 111t
 Hepatitis virus, murine, 43
 Herbal extracts, toxic leukoencephalopathy from, 128t
 Herbal medicine, 244, 245t
 Hereditary endotheliopathy, retinopathy, nephropathy, stroke
 (HERNS), 120t
 Hereditary optic neuropathy, Leber, 119t
 Hereditary spastic paraparesis, 121t
 HERNS (hereditary endotheliopathy, retinopathy, nephropathy,
 stroke), 120t
 Heroin, toxic effects of, 128t
 Herpes virus-6, human, 110t
 Heterogeneity of MS, 36
 Hexachlorophene, toxic leukoencephalopathy from, 128t
 History taking, 78t
 HIV-1 leukoencephalopathy, 109t
 Hope and optimism, 249-250, 251t

Hormone therapy, 181
 HTLV-1 myelopathy, 108t
 Human herpes virus-6, 110t
 Humoral disease, 40
 Humoral immunity, 45
 Hydroxyzine, 204
 Hyperreflexia, 206
 Hypertension, 240

ICAM-1, 43
 ICOMIN, 142, 156
 Imipramine (Tofranil), 196t, 201t
 Immune system
 herbs stimulating, 245t
 MS pathogenesis and, 43-47, 44, 46
 response to hepatitis B virus by, 39
 Immunoglobulin, intravenous, 145, 171t, 178
 for acute attack, 187, 188t, 189
 Immunoglobulin G
 in MS diagnosis, 76
 in pathological MS subtypes, 22t
 Immunoglobulin synthesis, 45-46
 Immunological disorders, differential diagnosis of, 95, 96t-100t
 Immunosuppressive therapy
 as disease-modifying treatment, 146
 future developments in, 181
 pathological MS subtype and, 25
 for PPMS, 161, 162
 for RRMS, 172
 IMPACT study, 139
 Incidence of MS, x
 Incontinence
 fecal, 208
 urinary. See *Bladder dysfunction*.
 Incoordination, cause of, 13
 Infarcts, subcortical, in CADASIL, 120t
 Infection
 fever management in, 232
 influenza, relapse after, 239
 in urinary tract, 193, 198-199
 causes of, 199
 drugs for, 198
 Infectious disorders
 differential diagnosis of, 95, 108t-111t
 MS risk and, 29
 Infiltrates, in pathological MS subtypes, 22t
 Inflammation, as cause/effect of tissue damage, 46, 46

Inflammatory demyelinating polyneuropathy, chronic, 98t
 Inflammatory disorders, differential diagnosis of, 95, 101t-103t
 Inflammatory ocular disease. See *Uveitis*.
 Influenza immunization, 239, 242t-243t
 Influenza infection, relapse after, 239
 Information for Handicapped Travelers, 258
 Insomnia, 188t
 Interferons
 antibodies to, 158
 as disease-modifying treatment, 134-135, 136t-138t, 139, 140, 141t, 142, 169. See also specific drugs.
 Interleukin (IL)-12, 45
 International Federation of Multiple Sclerosis Societies, 255
 International Multiple Sclerosis Support Foundation, 259
 Internet
 disease-modifying drug information on, 175t
 MS links on, 133, 257-260
 Intracorporeal injection therapy, 208
 Intractable symptoms, management of, 220-221
 Intravascular lymphoma, 124t
 Intussusception, 209
 Iron supplementation, for paroxysmal attacks, 207
 Irritable bowel syndrome, 208
 Isoniazid, 204

JHM coronavirus model, of MS in mice, 48
 Juvenile diabetes, 41

Kaplan-Meier curves
 of clinically isolated syndrome conversion to MS, 147, 148
 of time to disability in first four years, 152, 153
 Krabbe disease, 115t
 Kurtzke, five-year rule of, 229
 Kurtzke Disability Status Scale, 180

Laboratory tests, in MS workup, 78t
 Lactic acidosis, in MELAS, 118t
 Lamotrigine, 201t, 202
 Language-related symptoms, of paroxysmal attacks, 206
 Lapp population, MS risk in, 31
 Latitude, geographic, MS risk and, 27, 28-29
 Leber hereditary optic neuropathy, 119t
 Leber Stellate retinitis, 107t
 Legs
 restless, 206-207
 weakness in, 73
 Leigh syndrome, 119t

Leisure and recreation, 248

Lesions. See also *Plaques*.

- aging of, 14
- antimyelin response to, 47
- dissemination in space, 79, 80t-81t, 87t
- dissemination in time, 79, 80t, 88t
- heterogeneity of, 19
- MRI of, 52-53
- multiple, 13
- no better explanation for, 79, 83-84
- number of, future disease severity and, 59-61

Leukoariosis, 107t

Leukodystrophy

- adult onset, 95
 - autosomal dominant, 116t
- globoid cell, 115t
- metachromatic, 115t

Leukoencephalopathy

- in CADASIL, 120t
- after chemotherapy or radiation therapy, 125t
- in HIV-1, 109t
- progressive multifocal, 108t
- from therapeutic agents, 125t, 128t

Leukomalacia, periventricular, 129t

Levodopa, 207

Licorice, 245t

Lioresal (baclofen)

- for nystagmus, 212
- for pain, 189, 190t, 201t, 202
- for paroxysmal attacks, 207

Liver function tests

- in antifatigue drug monitoring, 194t-195t
- in antispasticity drug monitoring, 190t-191t

Localized disease, in McDonald Committee criteria, 80t-82t

Lumbar puncture, indications for, 93

Lupus erythematosus. See *Systemic lupus erythematosus*.

Lyme disease

- clinical features of, 108t
- MRI in, 108t

Lyme serology, 75, 78t

- negative, in Lyme encephalopathy, 90

Lymphoid irradiation, total, 178

Lymphoma

- of central nervous system, 124t
- intravascular, 124t

Macrophages, demyelination by, 17, 18, 19

Magnetic resonance angiography (MRA), spinal, 68

Magnetic resonance imaging (MRI)

- of abetalipoproteinemia, 122t
- of acute disseminated encephalomyelitis, 98t
- of adrenoleukodystrophy, 115t
- of adult onset autosomal dominant leukodystrophy, 116t
- of adult polyglusian body disease, 121t
- in advanced MS, 68
- of antiphospholipid antibody syndrome, 106t
- of atypical findings or unusual course, 66
- Avonex and, 135, 137t
- of Balo concentric sclerosis, 96t
- of Bechet disease, 101t
- Betaseron and, 137t, 165
- of Bickerstaff brain stem encephalitis, 98t
- of Binswanger disease, 107t
- of brucellosis, 110t
- of CADASIL, 120t
- of cardioembolic disease, 106t
- of celiac disease, 113t
- of central nervous system lymphoma, 124t
- of central pontine myelinolysis, 112t
- of central serous chorioretinopathy, 106t
- of cerebroretinal vasculopathy, 120t
- chemotherapy on, 128t
- of Chiari malformation, 126t
- of chronic inflammatory demyelinating polyneuropathy, 98t
- clinical/pathological correlation with, 51, 63, 64, 65-66
- of cobalamin deficiency, 112t-113t
- of Cogan syndrome, 104t
- contraindications to, 68
- Copaxone and, 137t
- of Degos disease, 105t
- of Devic disease, 97t
- in differential diagnosis, 61-63
- of dissemination in space, 79, 80t-81t, 87t
- of dissemination in time, 79, 80t, 88t
- drug abuse on, 128t
- of Eale disease, 101t
- environmental toxins on, 128t
- of eosinophilia-myalgia syndrome, 103t
- in established MS, 61-63, 64-65, 65-67
- of extrapontine myelinolysis, 112t
- of Fabry disease, 116t
- of folate deficiency, 113t
- of Friedreich ataxia, 117t
- functional, 69

- of globoid cell leukodystrophy, 115t
- of gluten sensitivity, 113t
- of Hashimoto encephalopathy, 112t
- head and spinal correlation in, 67
- of hepatitis C virus, 111t
- of hereditary spastic paraparesis, 121t
- of HERNs, 120t
- of HIV-1 leukoencephalopathy, 109t
- of HTLV-1 myelopathy, 108t
- of human herpes virus-6, 110t
- of intravascular lymphoma, 124t
- of Krabbe disease, 115t
- of Leber hereditary optic neuropathy, 119t
- of Leber Stellate retinitis, 107t
- of Leigh syndrome, 119t
- of leukoariosis, 107t
- of leukoencephalopathy after chemotherapy or radiation therapy, 125t
- limitations of, 71-72
- longitudinal, 63
- of Lyme disease, 108t
- of malignant angioendotheliomatosis, 124t
- of Marburg disease, 97t
- of MELAS, 118t
- of MERRF, 118t
- of metachromatic leukodystrophy, 115t
- of migraine, 107t
- of mitochondrial cytopathies, 117t
- of MNGIE, 118t
- monitoring disease activity with, 66-67
- of monosymptomatic demyelination, 96t
- monthly, 63, 65
- of motor neuron disease, 114t
- in MS workup, 78t
- of mycoplasma, 111t
- of NARP, 118t
- of neuroborreliosis, 108t
- of neuroretinitis, 107t
- of New Variant Creutzfeldt-Jakob disease, 109t
- nonspecificity of, 13
- Novantrone and, 137t
- occupational exposure to solvents on, 129t
- of olivopontocerebellar atrophy, 117t
- of organic acidemias, 116t
- of paraneoplastic disease, 124t
- of periventricular leukomalacia, 129t
- of porphyria, 122t

- predictive value of
 - in conversion of symptoms to MS, 54-55, 56t, 57
 - in severity of disease, 58-61, 60t
- prognosis and, 230t
- of progressive multifocal leukoencephalopathy, 108t
- of progressive necrotic myelopathy, 127t
- of psychiatric disease, 129t
- Rebif and, 137t
- in refractory disease, 66
- research applications of, 67
- of sarcoidosis, 102t
- of Schilder disease, 96t
- sensitivity vs specificity of, 55, 57, 58
- of Sjögren syndrome, 102t
- of Sneddon syndrome, 105t
- of spinal cord
 - head MRI correlation with, 67
 - indications for, 78t
 - sensitivity of, 68
- of spinal vascular malformations, 127t
- of spinocerebellar ataxia, 117t
- of spondylosis, 126t
- of sprue, 113t
- of subacute necrotizing encephalomyelopathy, 119t
- of subacute sclerosing panencephalitis, 110t
- of Susac syndrome, 104t
- in suspected or early MS, 54-61, 56t, 57, 60t, 62
- of syphilis, 109t
- of systemic lupus erythematosus, 103t
- techniques in, 51, 52-53
- of transverse myelitis, 96t
- of tumefactive MS, 97t
- typical findings in MS, 51, 52-53, 54
- of Usher's syndrome, 120t
- of uveitis, 104t
- of vasculitis, 105t
- of venous occlusive disease, 106t
- of vitamin B₁₂ deficiency, 112t-113t
- of vitamin E deficiency, 122t
- of Whipple disease, 108t
- of Wilson disease, 121t
- Magnetic resonance spectroscopy (MRS), 68-69, 70
- Magnetic resonance venography (MRV), 68
- Major histocompatibility complex (MHC) gene
 - autoimmune disease link to, 39
 - MS link to, 34
- Malignant angioendotheliomatosis, 124t

Marburg disease, 97t
 Mayo Clinic Patient Information Site, 259
 McDonald Committee criteria for MS
 definite on clinical grounds, 80t-82t
 dissemination in space, 79, 80t-81t, 87t
 dissemination in time, 79, 80t, 88t
 formula in, 79
 localized disease in, 80t-82t
 monosymptomatic attack in, 80t-81t, 83t, 96t
 MRI in, 85, 88-89
 multifocal attack in, 80t-82t
 no better explanation in, 79, 83-84
 primary-progressive disease in, 80t-81t, 83t
 red flags in
 genetic, 85t
 for MRI criteria for dissemination in space, 87t
 for MRI criteria for dissemination in time, 88t
 neurologic, 84t, 88
 psychiatric, 86t
 visual evoked response in, 83t, 85
 MCP-1, 43
 MDMA (ecstasy), 128t
 Measles immunization, 242t-243t
 Measles virus, 46
 Medic Alert Foundation, 258
 MELAS (mitochondrial encephalopathy with lactic acidosis and
 strokelike episodes), 118t
 Menses, MS attacks and, 235
 Mercury exposure, 128t
 MERRF (myoclonic epilepsy with ragged red fibers), 118t
 Metabolic disorders, differential diagnosis of, 112t-114t
 Metachromatic leukodystrophy, 115t
 Methanol, occupational exposure to, 129t
 Methotrexate, 161, 178
 Methylprednisolone
 as disease-modifying treatment, 146
 dosage of, 188t
 intravenous, 146, 171t
 oral vs intravenous, 186
 Mexiletine, 201t
 Microbes, MS link to, 29-30, 34
 Microglial activation, 19
 Migraine, 72, 91-92
 clinical features of, 107t
 MRI of, 107t
 Migration and MS risk, 27
 Milk of magnesia, 210

Mini Mental Status Exam, 215
 Mistletoe, 245t
 Mitochondrial cytopathies, 117t
 Mitochondrial encephalopathy with lactic acidosis and strokelike
 episodes (MELAS), 118t
 Mitochondrial neurogastrointestinal encephalopathy (MNGIE),
 118t
 Mitoxantrone. See *Novantrone*.
 MNGIE (mitochondrial neurogastrointestinal encephalopathy),
 118t
 Modafinil (Provigil), 195t
 Molecular immunology, MS pathogenesis and, 43-47, 44, 46
 Molecular mimicry, 45
 Monoclonal antibody administration, 181
 Monosymptomatic demyelination, xi, 96t
 Avonex for, 147
 clinical trials of, 147-149
 disease-modifying treatment of, 146-150, 150, 168-169
 in McDonald Committee criteria, 80t-81t, 83t. See also *Clini-
 cally isolated syndrome*.
 Mood swings, 219
 Motor disorders, 114t. See also *Ambulation/movement disorders*.
 MRA. See *Magnetic resonance angiography*.
 MRI. See *Magnetic resonance imaging*.
 MRS. See *Magnetic resonance spectroscopy*.
 MS International Foundation, 181
 MS National Center, 254
 MS societies, 254-255
 Multidisciplinary MS clinic, 220-221
 Multifocal attack, in McDonald Committee criteria, 80t-82t
 Multiple Sclerosis Society of Canada, 254
 Multiplex families, MS in, 31
 Mumps immunization, 242t-243t
 Muscle blockade, 184t
 Mushrooms, 245t
 Mycoplasma, 111t
 Myelin, normal, 14
 Myelin-associated glycoprotein, 22t-23t
 Myelination diffuse sclerosis, 96t
 Myelinolysis, central pontine or extrapontine, 112t
 Myelin-producing cells, replenishment of, 181
 Myelitis, transverse, 96t
 Myelography, indications for, 68
 Myelopathy
 in Eale disease, 101t
 in HTLV-1, 108t
 progressive necrotic, 127t
 Myoclonic epilepsy with ragged red fibers (MERRF), 118t

NARP (neuropathy ataxia and retinitis pigmentosa), 118t
 NASP Betaseron, 139
 National Council on Independent Living (NCIL), 258
 National Institutes of Health, 259
 National Multiple Sclerosis Society (NMSS), 133, 178, 225t, 226, 247, 254
 Physician Consultation Service of, 260
 on RRMS treatment, 152
 Natural history of MS
 modification of, 228
 over three decades, 227, 228
 NCIL (National Council on Independent Living), 258
 Necrotic myelopathy, progressive, 127t
 Necrotizing encephalomyelopathy, subacute, 119t
 Neoplasms, differential diagnosis of, 69, 70
 Nephropathy, in HERNS, 120t
 Neuroborreliosis. *See Lyme disease.*
 Neurogastrointestinal encephalopathy, mitochondrial (MNGIE), 118t
 Neuroimaging, 51-72
 Neurological examination, 78t
 Neurological factors in MS diagnosis, 84t, 88
 equivocal, 89-91
 major, 94-95, 130
 minor but definite, 91-94
 Neurologist, role in patient education, 224-226, 225t
 Neuromyelitis optica, 97t
 Neurontin (gabapentin)
 for nystagmus, 212
 for pain, 199, 200t, 202
 for paroxysmal attacks, 207
 Neuro-ophthalmological symptoms, 211-212
 Neuropathy
 with ataxia and retinitis pigmentosa (NARP), 118t
 Leber hereditary optic, 119t
 Neuroprotective medication, pathological MS subtype and, 25
 Neuroretinitis, 107t
 Neurovascular decompression, 202
 New variant Creutzfeldt-Jakob disease, 109t
 Nitrates, sildenafil contraindication with, 208
 Nitrofurantoin, in pregnancy, 198
 Nitrous oxide, toxic effects of, 128t
 NMSS. *See National Multiple Sclerosis Society.*
 No better explanation, for MS symptoms, 79, 83-84
 Nonsteroidal anti-inflammatory drugs, 201t
 Nordic extraction, MS risk in, 30

Nortriptyline (Pamelor)
 for emotional disorders, 219
 for pain, 200t
 Novantrone (mitoxantrone)
 administration of, 176t
 advantages and disadvantages of, 140t
 adverse effects of, 143-145, 176t-177t, 177
 as anticancer drug, 143
 as cardiotoxin and carcinogen, 144-145, 159, 177
 clinical trials of, 137t, 144
 dosage of, 136t, 144, 159, 176t-177t
 effectiveness of, 136t, 144, 161
 failure of, 177-178
 laboratory monitoring of, 140t
 laboratory tests before, 176t, 177
 MRI after, 137t
 patient education about, 175t, 176t
 patient monitoring in, 174, 176t-177t, 177
 patient selection for, 141t, 145, 155
 for PPMS, 161
 in pregnancy, 154
 for PRMS, 136t, 163, 163
 for RRMS, 171t
 for SPMS, 159
 teratogenicity of, 237
 Web site for, 175t
 Nystagmus, drugs for, 212

 Obesity, 240
 Occupational therapists, for ambulation/movement disorders, 204
 Occupational toxins, solvents, 128t
 Offspring of MS patients, 31, 32t
 Oligoclonal bands, 76-77, 79
 Oligodendrocytes
 loss of, in pathological MS subtypes, 22t
 transplantation of, 172
 Oligodendroglial cells, 14
 Olivopontocerebellar atrophy, 117t
 Oncological disease, differential diagnosis of, 95, 124t-125t
 ONSG (Optic Neuroitis Study Group) trial, 186-187
 Ophthalmoplegia, 94
 in Eale disease, 101t
 Optic nerves, lesions in, 76
 Optic neuritis, 13, 14
 conversion to MS, 54, 56t, 147
 in Eale disease, 101t
 recurrent, 91-92

- relapse of, 186
- treatment of, 212
- Optic Neuritis Study Group (ONSG) trial, 186-187
- Optic neuropathy, Leber hereditary, 119t
- Optimism and hope, 249-250, 251t
- Oral contraceptives, 233-235
- Organic acidemias, 116t
- Oriental population, MS risk in, 31
- Oxybutynin (Ditropan), 196t

- Pain in MS
 - causes of, 199
 - during childbirth, 235
 - drugs for, 199, 200t-201t
 - radiofrequency rhizotomy or neurovascular decompression for, 202
 - types of, 202
- Painter's syndrome, chronic, 129t
- Pamelor (nortriptyline)
 - for emotional disorders, 219
 - for pain, 200t
- Panencephalitis, subacute sclerosing, 46, 110t
- Panic disorder, 90
- Paraneoplastic disease, 124t
- Paraparesis
 - hereditary spastic, 121t
 - progressive, 94
- Parent(s) with MS, MS risk in offspring of, 31, 32t
- Paresthesias
 - benign, 90, 224
 - cause of, 13
 - recurrent, 73
- Paroxetine (Paxil), 219
- Paroxysmal attacks
 - of brain stem dysfunction
 - frequency of, 205
 - symptoms of, 205-206
 - differential diagnosis of, 206
 - other than brain stem, 206
 - seizures in, 207
 - sleep-related, 206
 - treatment of, carbamazepine in, 206
- Pathogenesis of MS, 39. See also *Risk factors for MS*.
 - molecular immunology and, 43-47, 44, 46
 - stage of, animal models and, 41
- Pathological MS subtypes, 20-21
 - demyelinating patterns in, 24t
 - structural and immunological features of, 19, 22t-23t
 - treatment options and, 25
- Pathology of MS, 14, 17, 18, 19
- Patient, revealing diagnosis to, 223-226, 225t
- Patient counseling, about disease-modifying treatments, 166-168
- Patient education
 - in diagnostic revelation, 224-226, 225t
 - on disease-modifying treatment, 154-155
 - in treatment decisions, xi
- Paxil (paroxetine), 219
- Pemoline (Cylert), 194t
- Penile prosthesis, 208
- Peptide immunization, 181
- Pergolide, 207
- Peri-colase (casanthranol-docusate), 210
- Periodic limb movements of sleep, 206-207
- Periventricular lesion, 55, 57
- Periventricular leukomalacia, 129t
- PET (positron emission tomography), 69
- Phenol, for spasticity, 189
- Phenytoin (Dilantin)
 - for pain, 201t, 202
 - for seizures, 207
- Physical therapy
 - for ambulation/movement disorders, 203
 - for spasticity, 189
- Plaques. See also *Lesions*.
 - characteristics of, 14, 16-17
 - in demyelination, 13, 14
 - location of, 14
 - MRI of, 52-53
 - patterns and locations of, 48
 - shape of, in pathological MS subtypes, 22t
 - ultrastructure of, 17, 18, 19
 - white matter transformation into, 48-49
- Plasma exchange, 145, 171t, 178
 - for acute attack, 187, 188t, 189
- Pleocytosis, 76
- Pneumococcal immunization, 242t-243t
- Polio immunization, 242t-243t
- Polyglusan body disease, adult, 121t
- Porphyria, 122t
- Positron emission tomography (PET), 69
- Postinfectious syndrome, 92
- Postpartum period, relapse rate during, 234, 235-237
- Post-traumatic syndrome, 72
- Potassium replacement, 188t

PPMS. See *Primary-progressive MS*.

Pramipexole, 207

Predictive value of MRI, 54-55, 56t, 57, 60t. See also *Prognosis of MS*.

Pregnancy

- child rearing responsibilities after, 235
- cytotoxic drug avoidance during, 237
- delivery analgesia in, 235
- disease-modifying treatments during, 154, 236
- MS susceptibility during, 27
- relapse rate during and after, 233-234, 234, 236
- urinary tract infection in, 198-199

Priapism, 208

Primary-progressive MS (PPMS)

- Copaxone for, 143
- definition of, 15
- in McDonald Committee criteria, 80t-81t, 83t
- MRI of, 65
- prevalence of, 17, 161
- PRMS distinction from, 163t
- time line for, 16
- treatment of, 161, 162

Primidone, 204

PRMS. See *Progressive-relapsing MS*.

Prognosis of MS

- disease heterogeneity and, 228
- five-year rule of Kurtzke in, 229
- individual variability in, 228-229
- modification of, 228
- MRI findings and, 58-61, 60t
- risk factors in, 230t-231t
- over three decades, 227, 228
- time to worsening in, 231t

Progressive multifocal leukoencephalopathy, 108t

Progressive necrotic myelopathy, 127t

Progressive-relapsing MS (PRMS)

- definition of, 15
- MRI of, 65
- PPMS distinction from, 163t
- prevalence of, 17
- time line for, 16
- treatment of, 161, 163, 163
 - Novantrone in, 136t, 163, 163

Proinflammatory cytokines, 45

Propranolol, 204

Protein level in blood, 76

Proton density MRI, 52-53

Provigil (modafinil), 195t

Prozac (fluoxetine)

- for bladder dysfunction, 194t
- for emotional disorders, 219

Pseudobulbar affect, 220

Psilocybin, 128t

Psychiatric disease, 72, 91

- differential diagnosis of, 129t
- MS with, 224

Psychiatric factors, in MS diagnosis, 86t, 90

Psychogenic symptoms

- of paroxysmal attacks, 206
- respiratory, 214

Psychosocial issues, disabling disease and, 246-248

Psychotic disorder, suicide risk in, 246

Psychotic states, 220

PTPRC gene product, MS link to, 34

Racial clustering of MS, 30-31

Radiation therapy

- leukoencephalopathy after, 125t, 128t
- total lymphoid, 178

Radiofrequency rhizotomy, 202

Radiosurgery, of brain, for ambulation/movement disorders, 205

Ragged red fibers, in MERRF, 118t

Ranitidine, 188t

RANTES, 43

Rapid plasma reagin, 78t

Rebif (interferon b1a)

- advantages and disadvantages of, 140t
- dosage of, 136t, 142
- effectiveness of, 136t, 142, 156
- failure of, 177-178
- laboratory monitoring of, 140t
- for monosymptomatic demyelination, 150
- MRI after, 137t
- patient education about, 173, 175t
- patient monitoring in, 140t
- patient selection for, 141t
- in pregnancy, 154, 236
- and progression to disability, 152, 153
- for RRMS, 156, 157, 158
- for SPMS, 160
- structure of, 142
- studies of, 137t, 142
- Web site for, 175t

Recreation and leisure, 248

Reference texts on MS, 253-254

Relapse

- criteria for, 185
- severity and responsiveness to treatment in, 185-186

Relapsing-remitting MS (RRMS)

- definition of, 15
- diagnosis of, 75-76
- dissemination in space in, 81t
- MRI of, 52-53
 - clinical correlation with, 63
 - disease severity prediction from, 60t
- prevalence of, 17
- prognosis of, 228
- progression to disability, 151, 152
- punctuated pattern of, 48
- relapse rate in, 169
- time line for, 16
- treatment of
 - algorithm for, 151
 - Avonex in, 135, 136t, 156-157, 157, 170t, 172
 - Betaseron in, 136t, 139, 156, 157, 158, 170t, 172
 - contraindications to, 154-155
 - Copaxone in, 136t, 143, 156-158, 157, 170t-171t, 172
 - drug selection in, 154-159
 - intravenous immunoglobulin for, 145
 - intravenous methylprednisolone for, 146
 - NMSS recommendations on, 152
 - Novantrone in, 136t, 155-156
 - patient selection for, 150-151
 - in pregnancy, 154
 - Rebif in, 156, 157, 158
 - steroids in, 187, 188t, 189
 - studies of, 152, 156
 - timing of, 66, 151-154
 - watchful waiting in, 151, 169

Remyelination, inhibition of, 25

Research in MS, 35-37

Resources on MS, 225t, 253-260

- Demos Medical Publishing, 255-257
- disease-modifying treatments. *See Treatment of MS, disease-modifying.*
- on Internet, 257-260
- MS societies, 254-255
- for physician consultation, 260
- reference texts, 253-254

Respiratory difficulty

- drugs for, 214

- pathogenesis of, 212
- predicting progression of, 212, 214
- psychogenic, 214
- rating of, 213t

Restless-legs syndrome, 206-207

Restoril (temazepam), 188t

Retinitis, Leber Stellate, 107t

Retinitis pigmentosa, in NARP, 118t

Retinopathy, in HERNs, 120t

Rheumatoid arthritis, suicide risk in, 246

Rheumatological disorders, differential diagnosis of, 95, 101t-103t

Rhizotomy, radiofrequency, 202

Risk factors for MS

- autoimmune conditions as, 30
- environmental, 30, 34-35
- in epidemic, 27, 29
- familial, 30, 32t-33t
- genetic, 31, 34-35
- geographic, 27, 28-29
- infectious, 29
- interaction among, 36-37
- mathematical modeling of, 37
- migration as, 27
- racial, 30-31
- sexual, 27
- viral, 36

Ropinirole, 207

RRMS. *See Relapsing-remitting MS.*

RTPRC gene, MS link to, 34

Rubella immunization, 242t-243t

Sagittal FLAIR MRI, 52-53

Sarcoidosis, 102t

Schilder disease, 96t

Schwann cells, replenishment of, 181

Scopolamine, for nystagmus, 212

Scopolia, 245t

Secondary-progressive MS (SPMS)

- definition of, 15
- MRI of
 - clinical correlation with, 63
 - disease severity prediction from, 60t
- prevalence of, 17
- time line for, 16
- treatment of, 159, 161, 171t
 - algorithm for, 160
 - Avonex in, 139, 160

- Betaseron in, 160
- Copaxone in, 160
- intravenous methylprednisolone in, 146
- Novantrone in, 136t, 160
- Rebif in, 160
- steroids in, 187
- Sedentary lifestyle, 208
- Seizures, 207
- Self-image, sexual dysfunction and, 207-208
- Semliki Forest virus, 43
- Senna, 245t
- Sensitivity of MRI, specificity vs, 55, 57, 58
- Sensory symptoms
 - of paroxysmal attacks, 206
 - prognosis and, 229
- Serotonin selective reuptake inhibitor (SSRI), 219
- Sertraline (Zoloft), 219
- Severity of disease, MRI prediction of, 58-61, 60t
- Sexual disturbances, 207-208
- Sexual inappropriateness, 219-220
- Shiitake mushroom, 245t
- Siblings, MS risk in, 31, 32t
- Sildenafil (Viagra), 207-208
- Single photon emission computed tomography (SPECT), 69
- Sjögren syndrome, 78t, 95
 - cardinal features of, 102t
 - MRI of, 102t
- Sleep-related disturbances, 206-207
- Sneddon syndrome, 105t
- Social Security Administration disability benefits, 248
- Solvents, occupational exposure to, 128t
- Somatization, 224
- Somatization disorder, 90
- Spastic paraparesis, hereditary, 121t
- Spasticity
 - definition of, 189
 - drugs for, 189, 190t-191t, 192
 - invasive treatment of, 189, 192
 - progression of, 189
 - in severity classification, 184t
 - sexual dysfunction and, 207-208
- Specificity of MRI, sensitivity vs, 55, 57, 58
- SPECT (single photon emission computed tomography), 69
- SPECTRIMS trial, 139
- Sperm, disease-modifying treatments and, 236
- Sphincter dyssynergia, 198

- Spinal cord
 - MRA of, 68
 - MRI of
 - head MRI correlation with, 67
 - indications for, 78t
- Spinal cord pathology, 13, 14, 54
 - differential diagnosis of, 95, 126t-127t
 - MRI of, 61
- Spinal vascular malformation, 127t
- Spinocerebellar ataxias, 117t
- Spirituality, 249
- SPMS. See *Secondary-progressive MS*.
- Spondylosis, 126t
 - ankylosing, suicide risk in, 246
 - cervical, 92
- Sprue, 113t
- St. John's wort, 245t
- Stem cell transplantation, 172, 181
- Steroids. See *Corticosteroids*.
- Stinging nettle, 245t
- Stretching exercises, 184t, 241
- Stroke
 - antimyelin response after, 47
 - in HERNs, 120t
 - suicide risk in, 246
- Strokelike episodes
 - in Eale disease, 101t
 - in MELAS, 118t
- Subacute necrotizing encephalomyelopathy, 119t
- Subacute sclerosing panencephalitis, 110t
- Substance abuse, differential diagnosis of, 128t
- Suicide risk, 246
- Surgery in MS, 232-233
- Surgical ablation, of brain, for ambulation/movement disorders, 205
- Susac syndrome, 104t
- Swimming, 241
- Sylvia Lawry Center, 181
- Symmetrel (amantadine), 194t
- Symptoms of MS. See *Clinical MS presentation*.
- Syphilis, 78t, 109t
- Systemic lupus erythematosus
 - cardinal features of, 103t
 - MRI of, 103t
 - MS link to, 35
 - pathogenesis of, 39, 40

- T cells
 - autoreactive, 43, 44
 - helper, 45
 - interaction with antigen-presenting cells, 44
 - vaccination with, 181
- T1-weighted MRI, 52-53
 - of MS clinical subtypes, 63, 65
- T2-weighted MRI, 51, 52-53
 - hyperintensities and demyelination on, 75
 - of MS clinical subtypes, 63, 65
 - prognosis and, 230t
 - sensitivity and specificity of, 55
- Tacrolimus, toxic leukoencephalopathy from, 128t
- Tai-Chi, 241
- Tegretol (carbamazepine)
 - for pain, 199, 200t-201t, 202
 - for paroxysmal attacks, 206
 - for seizures, 207
- Temazepam (Restoril), 188t
- Temperature, MS patient sensitivity to, 232, 240
- Tension headaches, 91
- Teratogenicity, of disease-modifying treatments, 236
- Tetanus immunization, 239, 242t-243t
- Theiler's murine encephalomyelitis virus, 42-43
- Thyroid disease, MS link to, 30, 41
- Thyroid function tests, 78t
- Tissue damage, as cause/effect of inflammation, 46, 46
- Tizanidine (Zanaflex), 189, 190t, 201t
- Tofranil (imipramine), 196t, 201t
- Tolterodine (Detrol), 196t-197t
- Toluene, 128t-129t
- Topiramate, 202
- Toxic disorders, differential diagnosis of, 95, 128t-129t
- Tramadol, 201t
- Transgenic technology, in EAE, 41
- Transplantation
 - of bone marrow, 181
 - of oligodendrocytes, 172
 - of stem cells, 172, 181
- Transverse myelitis, 96t
- Trazodone (Desyrel), 219
- Treatment of MS. See also *Clinical MS presentation*.
 - alternative and complementary medicine in, 244, 245t
 - anesthesia and surgery in, 232-233
 - animal models of, 42-43
 - in children, 237-239
 - complicated or intractable, 220-221
 - contraception and pregnancy in, 233-237, 234. See also *Pregnancy*.
 - disease-modifying. See *Disease-modifying treatments*.
 - EAE treatment vs, 42
 - early, long-term benefit of, xi
 - heat, fever, and infection in, 232
 - hope and optimism in, 249-250, 251t
 - individualization of, 133
 - leisure and recreation in, 248-249
 - patient involvement in, xi, 224-226, 225t
 - psychosocial issues and disability in, 246-248
 - revealing diagnosis to patient in, 223-226, 225t
 - spirituality in, 249
 - symptom severity and, 183, 184t
 - vaccination in, 239-240, 242t-243t
- Tremor
 - drugs for, 204-205
 - in upper extremities, 204
- Tricyclic antidepressants
 - for emotional disorders, 219
 - for pain, 199, 201t, 202
- Trigeminal neuralgia, 199, 202
- Trimethoprim-sulfamethoxazole (Bactrim), 198
- Tumefactive MS, 97t
- Tumor necrosis factor (TNF)- α , 45
- Twins, MS risk in, 30-31, 32t, 36

- U fibers, 52-53
- Urinary tract infection, 193
 - causes of, 199
 - drugs for, 198
- Usher syndrome, 120t
- Uveitis
 - clinical features of, 104t
 - MRI of, 104t
 - MS link to, 30, 41

- Vaccination in MS, 242t-243t, 239-240
- Vacuum erection devices, 208
- Vaginal lubricants, 208
- Valium (diazepam), 189, 190t
- Valproate, 201t, 207
- Varicella immunization, 242t-243t
- Vascular disorders
 - differential diagnosis of, 104t-107t
 - imaging of, 68
- Vascular malformation, spinal, 127t

Vasculitis, 105t
 differential diagnosis of, 78t
Vasculopathy, cerebroretinal, 120t
VCAM-1, 43
Venous occlusive disease, 106t
Vestibuloauditory dysfunction, in Eale disease, 101t
Viagra (sildenafil), 207-208
Vibrators, 208
Viral liver disease, suicide risk in, 246
Virus, MS caused by, 36
Visual disturbances
 cause of, 13
 monocular, 73
Visual evoked responses, 76, 78t
 in McDonald Committee criteria for MS, 83t, 85
Visual loss, 94
Vitamin B₁₂ deficiency or dysmetabolism, 112t
Vitamin B₁₂ level, 78t, 95
Vitamin E deficiency or dysmetabolism, 122t
Volatile fumes, inhalation of, 128t

Watchful waiting
 indications for, 93
 in monosymptomatic demyelination, 150
 in PPMS, 162
 in RRMS, 151, 169
 in SPMS, 160

Weakness
 cause of, 13
 in legs, 73

Wellbutrin (bupropion), 219
Whipple disease, 108t
White matter
 junction with gray matter, MRI of, 55, 57
 lesions in, causes of, 71
 T2-intense foci in, 51, 52-53
 transformation into plaque, 48-49
Wilson disease, 121t
Woody night-shade stem, 245t

Xylene, occupational exposure to, 129t

Yoga, 241

Zanaflex (tizanidine), 189, 190t, 201t
Zoloft (sertraline), 219
Zonisamide, 201t